Provectus Biopharmaceuticals, Inc. (PVCT) stock
PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.05+0.00 (+0.39%)
Close on Oct 19, 2026Market cap $20.55MP/E –Yield –
Provectus Biopharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Provectus Biopharmaceuticals's free cash flow for the twelve months ending Dec 31, 2017 was -$10.38M. For fiscal 2017 it was -$10.38M. The highest annual figure on record is -$8.60M in fiscal 2009.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | -$10.38M | – |
| FY2015 | Dec 31, 2015 | -$17.42M | – |
| FY2014 | Dec 31, 2014 | -$13.92M | – |
| FY2013 | Dec 31, 2013 | -$9.90M | – |
| FY2012 | Dec 31, 2012 | -$11.27M | – |
| FY2011 | Dec 31, 2011 | -$17.21M | – |
| FY2009 | Dec 31, 2009 | -$8.60M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2017 | Dec 31, 2017 | -$2.47M | – |
See a number that looks wrong?